Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Antibody-Drug Conjugate (ADC) Target Proteins
Antibody-Drug Conjugate (ADC) Target Proteins

Antibody-Drug Conjugate (ADC) Target Proteins

The target antigen plays a crucial role in distinguishing cancer cells from normal cells, thereby reducing off-target toxicity. Therefore, the selection of the appropriate target antigen is the initial step in developing an ideal ADC.
The ideal antigen should possess specific characteristics:
i) It should be highly expressed on the surface of cancer cells compared to healthy cells.  
ii) The binding site of the target antigen should be oriented towards the external surface of the cancer cell rather than the internal site, allowing the ADC to bind with the target antigen effectively upon diffusion from the bloodstream before internalization occurs.  
iii) The target antigen should not be secreted into the systemic circulation to prevent undesired binding of ADC outside the tumor.
iv) The target antigen should demonstrate the ability to internalize the bound ADCs effectively.
We have successfully developed a suite of over 90 high-quality ADC target proteins, encompassing a variety of species including Human, Mouse, Cynomolgus Monkey, and Rat, each equipped with diverse tags. These proteins with high purity and robust bioactivity, suitable for immunization, antibody screening, species validation, quality control, pharmacokinetic studies, and diverse applications.
Product Features
Comprehensive coverage of over 90 ADC target proteins;
Multiple species and tags available;
Proteins with uniform structure and high purity verified by SEC-MALS;
High bioactivity validated by ELISA/SPR/BLI/FACS, etc.
Validation Data
High purity verified by SEC-MALS
Dimer structure and purity of PSMA verified by SEC-MALS
PSMA dimer,  MALS-validated protein

The purity of Mouse PSMA Protein, Fc Tag (Cat. No. PSA-M5266) is more than 90% and the molecular weight of this protein is around 240-280 kDa verified by SEC-MALS.

High purity of LRRC15 verified by SEC-MALS
LRRC15, MALS-validated protein

The purity of Biotinylated Human LRRC15, His,Avitag (Cat. No. LR5-H82E4) is more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.

The binding activity verified by ELISA
PSMA dimer, binding activity validated by ELISA

Immobilized Monoclonal Anti-Human PSMA Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Human PSMA, His Tag (Cat. No. PSA-H52H3) with a linear range of 2-39 ng/mL (QC tested).

TROP-2, binding activity validated by ELISA

Immobilized Human TROP-2, His Tag (Cat. No. TR2-H5223) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

Claudin-18.2, binding activity validated by ELISA

Immobilized Human Claudin-18.2 Full Length Protein-VLP (Cat. No. CL2-H52P7) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.2-3 ng/mL (QC tested).

B7-H4, binding activity validated by ELISA

Immobilized Human B7-H4, His Tag (Cat. No. B74-H5222) at 2 μg/mL (100 μL/well) can bind Anti-B7-H4 MAb (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).

The binding activity verified by SPR
TROP-2, binding activity validated by SPR

Captured Trop2 antibody on CM5 chip via anti-mouse antibodies surface can bind Human TROP-2, His Tag (Cat. No. TR2-H5223) with an affinity constant of 5.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CDH17, binding activity validated by SPR

Anti-Cadherin-17 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human Cadherin-17, His Tag (Cat. No. CA7-H52H3) with an affinity constant of 2.9 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Nectin-4, binding activity validated by SPR

Mouse Anti-Nectin-4 Antibody (Mouse IgG1) captured on CM5 chip via anti-mouse antibodies surface can bind Human Nectin-4, His Tag (Cat. No. NE4-H52H3) with an affinity constant of 58.2 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

FRα, binding activity validated by SPR

Biotinylated Human FOLR1, His,Avitag (Cat. No. FO1-H82E2) immobilized on SA Chip can bind Folic acid-BSA with an affinity constant of 83.8 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).

The binding activity verified by BLI
B7-H3, binding activity validated by BLI

Loaded Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 on Protein A Biosensor, can bind Human B7-H3 Protein, His Tag (Cat. No. B73-H52E2) with an affinity constant of 479 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

ROR1, binding activity validated by BLI

Loaded Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, His,Avitag (Cat. No. RO1-H82E6) on SA Biosensor, can bind Zilovertamab with an affinity constant of 0.252 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Resources

Webinar playback and appointment

Addressing Challenges in Antibody-Drug Conjugate Development
Here is the brief recap of the webinar:ADCs have the potential to enable 'precision medicine' with a wide market reach.Challenges in ADCs include managing Target Affinity, enhancing payload conjugation, and assessing Payload Delivery in vivo Pharmacokinetics. We can provide high-quality solutions to address these challenges.
Addressing Challenges in Antibody-Drug Conjugate Development
Watch Now
Building the Perfect Antibody-based Therapeutic from Selection to Engineering and Manufacturing
In this webinar, discover how advanced techniques such as Al-driven candidate selection optimization of antibody sequences, and precise conjugation methods come together to address some of the current challenges in antibody-based therapeutics.
Addressing Challenges in Antibody-Drug Conjugate Development
Watch Now

Resource download

More core reagents for Antibody-drug conjugates (ADCs) development
AGLink® ADC site-specific conjugation kit: Powering your magic bullets
Fc Receptor Proteins - Partners for Antibody Drug Development
[Flyer]Fucntional Cell Lines and Development Service
Tools for ADC PK Analysis
Promotion
ACRO Quality

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message